Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450202 | 1.00 | KMT2A (0.57) | KMT2ANPC1RAB9APKMGAA | |
| Hydrochloric Acid SCHEMBL31097467 | 0.98 | KMT2A (0.55) | KMT2ANPC1RAB9APKMGAA | |
| SCHEMBL31097465 | 0.87 | KMT2A (0.52) | KMT2ANPC1RAB9APKMGAA | |
| SCHEMBL16827311 | 0.81 | KMT2A (0.44) | KMT2ANPC1RAB9APKMGAA | |
| SCHEMBL5186810 | 0.81 | KMT2A (0.49) | KMT2ANPC1RAB9APKMGAA | |
| SCHEMBL13479804 | 0.80 | KMT2A (0.52) | KMT2ANPC1RAB9APKMGAA | |
| SCHEMBL14312163 | 0.80 | KMT2A (0.52) | KMT2ANPC1RAB9APKMGAA | |
| SCHEMBL30205876 | 0.79 | CYP2A6 (0.46) | KMT2ANPC1RAB9APKMMEN1 | |
| SCHEMBL29676976 | 0.79 | KMT2A (0.50) | KMT2ANPC1RAB9APKMGAA | |
| SCHEMBL8658474 | 0.79 | KMT2A (0.50) | KMT2ANPC1RAB9APKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590078-B2 | — | — | 2026-03-31 | — | — | US | disclosed |
| US-20240293364-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20230338337-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230313313-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20220213059-A1 | INHIBITING USP19 | Valo Health, LLC | 2022-07-07 | — | — | US | disclosed |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293364-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | MSH2, MRE11, RAD50 | KMT2A 925/4885NPC1 4702/4885RAB9A 2019/4885 |
| US-20230313313-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | SKP2, MDM2, TP53 | KMT2A 517/4885NPC1 4095/4885RAB9A 4041/4885 |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | KMT2A 561/4885NPC1 3728/4885RAB9A 1788/4885 |
| US-20220213059-A1 | INHIBITING USP19 | USP19, UBQLN2, UBQLN1 | KMT2A 2533/4885NPC1 3955/4885RAB9A 315/4885 |
| US-12590078-B2 | — | ADRM1, USP19, USP1 | KMT2A 2342/4885NPC1 3279/4885RAB9A 165/4885 |
| US-20230338337-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | IRF2BP2, BST2, IRF3 | KMT2A 3768/4885NPC1 3750/4885RAB9A 1242/4885 |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | KMT2A 561/4885NPC1 3728/4885RAB9A 1788/4885 |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | KMT2A 3047/4885NPC1 2987/4885RAB9A 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.